Lantern Pharma Inc. has 180 calendar days, expiring March 24, 2027, to regain compliance with Nasdaq listing standards after receiving a delisting notice on September 25, 2026. The Nasdaq Stock Market LLC cited the company's failure to meet the market value of listed securities (MVLS) requirement, which mandates a minimum of $35,000,000.
In its Form 8-K filed with the Securities and Exchange Commission, Lantern Pharma disclosed that the notice identified non-compliance with Nasdaq Listing Rule 5550(b)(2). The company's common stock traded below the $35,000,000 MVLS threshold for the preceding 30 consecutive business days. Nasdaq also flagged deficiencies in Listing Rules 5550(b)(1) and 5550(b)(3).
To maintain its listing on the Nasdaq Capital Market, Lantern Pharma must cure the MVLS deficiency within the stipulated compliance period. If the company pursues this specific route to regain compliance, its market value of listed securities must close at or above $35,000,000 for a minimum of 10 consecutive business days. The filing notes that if compliance is not restored by the deadline, the company expects Nasdaq to issue a notice that its securities are subject to delisting.
Lantern Pharma Inc., headquartered in Dallas, Texas, is incorporated in Delaware and trades under the ticker symbol LTRN. The report was signed by David Margrave, the company's Chief Financial Officer, on October 1, 2026.